ClinPhone and invivodata create a new global partnership to provide electronic patient reported outcomes (ePRO) solutions.
Nottingham, UK, and Pittsburgh, PA- April 30, 2008-ClinPhone ( www.clinphone.com ), the world’s largest Clinical Technology Organization and invivodata ( www.invivodata.com ), the leading provider of device-based eDiaries, announced today an exclusive new global partnership to provide electronic patient reported outcomes (ePRO) solutions.
This new partnership will deliver best-of-breed offerings for the two most commonly used ePRO modalities-device-based and IVRS (Interactive Voice Response System) to pharmaceutical and biotech companies. As part of this collaboration, ClinPhone joins invivodata’s PROPartner™ Program, which enables invivodata customers to leverage the strengths of an impressive roster of affiliate technology and service companies whose offerings have been identified as “best-in-class” in their respective market areas.
The alliance between these two industry leaders brings customers a combination of support and expertise that surpasses anything currently offered in the marketplace in terms of helping them understand which modality would be best suited for their study.
ClinPhone and invivodata both focus heavily on regulatory and psychometric validation issues. In addition, both companies have strong relationships with industry thought leaders and instrument authors, furthering the value that this partnership will bring to customers.
Doug Engfer, founder, president, and chief executive officer of invivodata stated, “Successful use of ePRO today requires an in-depth understanding of scientific and regulatory considerations, coupled with appropriate technology and complete global support services. invivodata and ClinPhone have collaborated on and shared in many of the same efforts, organizations and events designed to promote sound ePRO research. This formal partnership strengthens this collaboration and delivers real value and best-of-breed solutions to our clients.”
Steve Kent, chief executive officer of ClinPhone, commented, “Usage of PRO and ePRO in clinical trials is increasing. By offering invivodata’s device-based ePRO options to our customers, we can expand our ability to meet their broader ePRO needs. This partnership also means we are able to provide sponsors with additional balanced and science-based guidance in line with evolving regulatory considerations.”
ClinPhone ePRO is renowned as an industry-leading IVR-based solution and offers an intuitive and easy-to-use solution for capturing patient self-reported data. This ranges from simple diaries to sophisticated health-related quality of life instruments. invivodata’s device-based ePRO solutions are based on over 20 years of experience, combining the scientific and regulatory expertise needed for ePRO with practical technology and proactive services to deliver accurate and reliable PRO data to clinical trial sponsors.
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
Behind the Buzz: Why Clinical Research Leaders Flock to SCOPE Summit
February 7th 2025In this episode, we meet with Micah Lieberman, Executive Conference Director for SCOPE Summit (Summit for Clinical Ops Executives) at Cambridge Innovation Institute. We will dive deep into the critical role of collaboration within the clinical research ecosystem. How do we bring together diverse stakeholders—sponsors, CROs, clinical trial tech innovators, suppliers, patients, sites, advocacy organizations, investors, and non-profits—to share best practices in trial design, program planning, innovation, and clinical operations? We’ll explore why it’s vital for thought leaders to step beyond their own organizations and learn from others, exchanging ideas that drive advancements in clinical research. Additionally, we’ll discuss the pivotal role of scientific conferences like SCOPE Summit in fostering these essential connections and collaborations, helping shape the future of clinical trials. Join us as we uncover how collective wisdom and cross-industry partnerships are transforming the landscape of clinical research.
FDA-Approved Gene Therapy Beqvez Shows Sustained Efficacy, Safety in Long-Term Hemophilia B Trial
April 17th 2025Beqvez (fidanacogene elaparvovec), an FDA-approved one-time gene therapy for hemophilia B, demonstrated sustained factor IX expression, low bleeding rates, and a favorable safety profile over long-term follow-up.